Protalix Biotherapeutics, Inc. (PLX)
2.48
+0.08
(+3.33%)
USD |
NYAM |
Aug 26, 16:00
2.475
0.00 (0.00%)
After-Hours: 20:00
Protalix Biotherapeutics Price to Book Value : 2.798 for Aug. 26, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 26, 2026 | 2.798 |
| August 25, 2026 | 2.708 |
| August 24, 2026 | 2.719 |
| August 21, 2026 | 2.686 |
| August 20, 2026 | 2.686 |
| August 19, 2026 | 2.652 |
| August 18, 2026 | 2.640 |
| August 17, 2026 | 2.584 |
| August 14, 2026 | 2.505 |
| August 13, 2026 | 2.663 |
| August 12, 2026 | 2.956 |
| August 11, 2026 | 2.742 |
| August 10, 2026 | 2.798 |
| August 07, 2026 | 2.776 |
| August 06, 2026 | 2.753 |
| August 05, 2026 | 2.753 |
| August 04, 2026 | 2.674 |
| August 03, 2026 | 2.618 |
| July 31, 2026 | 2.674 |
| July 30, 2026 | 2.561 |
| July 29, 2026 | 2.561 |
| July 28, 2026 | 2.629 |
| July 27, 2026 | 2.708 |
| July 24, 2026 | 2.674 |
| July 23, 2026 | 2.674 |
| Date | Value |
|---|---|
| July 22, 2026 | 2.674 |
| July 21, 2026 | 2.663 |
| July 20, 2026 | 2.719 |
| July 17, 2026 | 2.686 |
| July 16, 2026 | 2.607 |
| July 15, 2026 | 2.629 |
| July 14, 2026 | 2.607 |
| July 13, 2026 | 2.697 |
| July 10, 2026 | 2.753 |
| July 09, 2026 | 2.674 |
| July 08, 2026 | 2.686 |
| July 07, 2026 | 2.663 |
| July 06, 2026 | 2.595 |
| July 02, 2026 | 2.618 |
| July 01, 2026 | 2.595 |
| June 30, 2026 | 2.629 |
| June 29, 2026 | 2.816 |
| June 26, 2026 | 2.756 |
| June 25, 2026 | 2.661 |
| June 24, 2026 | 2.685 |
| June 23, 2026 | 2.601 |
| June 22, 2026 | 2.589 |
| June 18, 2026 | 2.661 |
| June 17, 2026 | 2.421 |
| June 16, 2026 | 2.469 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Altimmune, Inc. | 1.292 |
| Taysha Gene Therapies, Inc. | 5.057 |
| Humacyte, Inc. | 6.057 |
| Agenus, Inc. | -- |
| Amgen, Inc. | 20.37 |
Price to Book Value Related Metrics
| PE Ratio | 10.92 |
| PS Ratio | 2.514 |
| PEG Ratio | 0.0528 |
| Price to Free Cash Flow | 26.43 |
| Price | 2.48 |
| Earnings Yield | 9.16% |
| Market Cap | 199.82M |
| PEGY Ratio | 0.0528 |
| Operating PE Ratio | 8.701 |
| Normalized PE Ratio | 10.93 |